EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study



Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study



Investigational New Drugs 25(2): 173-180



Background: Oxaliplatin-induced neurotoxicity is a growing, relevant clinical problem. In this study we evaluated the efficacy and safety of carbamazepine for prevention of oxaliplatin-associated neuropathy in patients with advanced colorectal cancer.Methods: Chemotherapeutic treatment consisted of oxaliplatin 85 mg/m(2) given biweekly and weekly folinic acid 500 mg/m(2) followed by a 24-h infusion of 5-FU 2000 mg/m(2) (FUFOX). One cycle consisted of six consecutive weeks of treatment followed by two weeks of rest (=Treatment B). For Treatment A carbamazepine was added in a dosage for targeted plasma levels of 4-6 mg/L.Neurotoxicity was regularly assessed using a specific scale. Moreover, an evaluation of chronic sensory symptoms and a neurologic examination including tests for vibrational sense, strength and deep tendon reflexes were added creating a peripheral neuropathy (PNP) score.Results: The prospectively defined adequate number of patients needed to provide power for the primary outcome could not be achieved. 19 patients were assigned to Treatment A and 17 to Treatment B. At baseline, the distribution of all clinicopathologic variables was comparable between the two groups. Overall response rates were 16% and 24% and overall survival 15.1 months and 17.4 months for Treatment A and Treatment B, respectively. Between Treatment A and Treatment B there were no major differences when considering worst neurotoxicity during the study period (p=0.46). Grade 3/4 neurotoxicity occured in 4 patients with Treatment A vs. 6 patients with Treatment B. There were no major differences between both groups in each category of the PNP score.Conclusions: Based on the small number of patients and low statistical power of our study definite conclusions regarding efficacy and safety of carbamazepine for prevention of oxaliplatin-associated neuropathy in patients with advanced colorectal cancer cannot be drawn.

(PDF emailed within 0-6 h: $19.90)

Accession: 012842920

Download citation: RISBibTeXText

PMID: 16983507

DOI: 10.1007/s10637-006-9010-y



Related references

Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clinical Cancer Research 10(12 Pt 1): 4055-4061, 2004

Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomised phase II study. Annals of Oncology 21(10): 2121; Author Reply 2121-2, 2011

Resectability of liver metastases (LM) in patients with advanced colorectal cancer (ACRA) after treatment with the combination of oxaliplatin (OXA), irinotecan (IRI) and 5FU. Final results of a phase II study. Journal of Clinical Oncology 23(16_suppl): 3618-3618, 2016

Capecitabine in combination with oxaliplatin as first line therapy for patients with advanced or metastatic colorectal cancer Preliminary results of an international multicenter phase II study. European Journal of Cancer 37(Supplement 6): S272, October, 2001

Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicenter phase II study. Annals of Oncology 13(1): 103-107, 2002

Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study. European Journal of Cancer 35(3): 380-385, 1999

Final results of a randomized phase III study evaluating the addition of oxaliplatin first line to 5-FU followed by irinotecan at progression in advanced colorectal cancer (LIFE study). Journal of Clinical Oncology 23(16_suppl): 3517-3517, 2016

Oxaliplatin and irinotecan chemotherapy in advanced gastric cancer. Final results of a multicenter phase II trial. Journal of Clinical Oncology 24(18_suppl): 4070-4070, 2016

Randomised, multicenter phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer Confirmation of dose escalation. British Journal of Cancer 88(Supplement 1): S22, July, 2003

Oxaliplatin Clinical experience of phase I and II trials and results of a randomised phase II-III trial in first-line therapy advanced colorectal cancer. Fiebig, H H , Burger, A M Contributions to Oncology; Relevance of tumor models for anticancer drug development 331-341, 1999

Multicenter phase II study of modified FOLFIRI in patients in a Chinese population with advanced colorectal cancer (CRC) refractory to fluoropyrimidine and oxaliplatin. Journal of Clinical Oncology 23(16_suppl): 3686-3686, 2016

Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer. Clinical Colorectal Cancer 2(1): 54-58, 2002

Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. Journal of Clinical Oncology 20(6): 1512-1518, 2002

Oxaliplatin and raltitrexed in advanced colorectal cancer patients Preliminary results of a phase II study. International Journal of Antimicrobial Agents 17(Supplement 1): S21, June, 2001

Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet. Oncology 16(8): 979-989, 2015